<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[International Journal of Ophthalmology Press -->Informatics Research]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effects of immunosuppressants after penetrating keratoplasty: meta-analysis of randomized controlled trials]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201105014]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To assess the effectiveness of immunosuppressants in the prophylaxis of corneal allograft rejection after high-risk keratoplasty and normal-risk keratoplasty. 
METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CNKI, VIP and reference lists of articles. Date of most recent search: 18 June, 2011. All randomised controlled trials (RCTs) assessing the use of immunosupressants in the prevention of graft rejection, irrespective of publication language. Two authors assessed trial quality and extracted data independently. Only dichotomous outcomes (clear graft survival, ratio of immune reactions and side effects) were available and were expressed as relative risk (RR) and 95% confidence intervals (CI).
RESULTS: Seven studies were included in this review. In the comparing of mycophenolate mofetil (MMF) with placebo, the results showed MMF could significantly reduce immune reactions compared with placebo (RR 1.08 95% Cl 0.95 to 1.21), but no effect on clear graft survival (RR 1.11 95% Cl 0.90 to 1.35). In clear graft survival and immune reactions, MMF and cyclosporine A (CsA) showed similar effect (RR 1.11 95% Cl 0.90 to 1.35, and RR 1.48, 95% Cl 0.56 to 3.93, respectively). Tacrolimus (FK506) and steroid showed similar effects on clear graft survival and immune reactions (RR 0.32, 95% CI 0.02 to 6.21, and RR 1.00, 95%CI 0.88 to 1.14, respectively). No drug relative side effect has been found.
CONCLUSION: MMF may reduce immune reactions in both normal-risk and high-risk rejection of penetrating keratoplasty. CsA and FK506 showed similar effects as MMF. However, due to the lack of large clinical trials, the evidence remain weak, the quality of evidences were rated as very low to moderate. Large, properly randomised, placebo-controlled, double masked trials are needed to evaluate the effect of immunosuppressants.
]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Xin Wei,Xiao-Ming Chen,Lin Wang,Jin-Ping Song and Yin-Ping Deng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Xin Wei,Xiao-Ming Chen,Lin Wang,Jin-Ping Song and Yin-Ping Deng</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201105014]]></guid><cfi:id>34</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of ultrasound microbubble contrast technology in ophthalmic targeted therapy: literature analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201105015]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To analyze the application of microbubble contrast technology in the treatment of ophthalmic diseases, mainly analyzing its advantages and existing problems.  
METHODS: A total of 30 representative literatures about the application of ultrasound contrast agent in gene targeted therapy at home and abroad were collected, and focusing on sorting out the literature reporting the treatment of ophthalmic diseases with microbubble contrast technology in recent years, then recalling its advantages and problems, finally making reasonable assessment on existing problems and proposing possible solutions to the problems. 
RESULTS: Due to its unique safety and efficacy, the treatment of ophthalmic diseases with microbubble contrast technology has increasingly drawn the attention of clinicians, but two relevant issues should be considered: first, the nature of contrast agent and the choice of corresponding ultrasound parameters; second, relative incidence of tissue bleeding, intravascular hemolysis, moderate or severe allergy as well as other side effects. 
CONCLUSION: Microbubble may become the carrier of targeted therapy, and as a kind of new non-invasive delivery system, the ultrasound contrast agent has broad application prospects, but its application in ophthalmic research is still in its initial stage and the safety of contrast-enhanced ultrasound still needs further study.
]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Jia-Ying Yuan,Jian-Hua Zhang,Chong Tang,Hong Zhu,Hua Xie and Shuan-Jie Gao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Jia-Ying Yuan,Jian-Hua Zhang,Chong Tang,Hong Zhu,Hua Xie and Shuan-Jie Gao</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201105015]]></guid><cfi:id>33</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Bibliometric study of diabetic retinopathy during 2000-2010 by ISI]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201104001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To analyze the progress in diabetic retinopathy (DR) researches between 2000 and 2010 through bibliometric study. 
METHODS: Using ISI Web of Science database for statistical sources, we retrieved DR literatures during 2000-2010, analyzed "the number of published articles per year, authors, source publications, subject category, document type, document language, institution and country/region" by bibliometric statistical methods. 
RESULTS: The total number of published articles that were retrieved for the years during 2000-2010 was 8590. DR researches changed as a linear upward trend, the main researches focused on ophthalmology, endocrine and metabolic diseases. Article was the main document type. Harvard University was the major research institution.  
CONCLUSION: There has achieved a significant increase in the number of ISI publications and collaborations in DR literatures from 2000 to 2010. With the rising of the number of diabetes in the world, diabetic retinopathy has become a focus of scientific researches. 
]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Lei Liu,Jing-Hua Jiao and Lei Chen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Lei Liu,Jing-Hua Jiao and Lei Chen</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201104001]]></guid><cfi:id>32</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of ultrasound contrast in identification and diagnosis of ocular spaceoccupying lesions]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201104002]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To analyze the application significance of ultrasound contrast agent in identification and diagnosis of ocular spaceoccupying lesions, and mainly analyze its advantages and problems.
METHODS: Thirty-two representative literatures about the application of ultrasound contrast agent in diagnosis of spaceoccupying lesions at home and abroad were collected after focused on sorting the literature reporting the application of ultrasound contrast diagnostic technology in the diagnosis and identification of ocular spaceoccupying lesions in recent years. Its advantages and problems were retrospectively analyzed, and reasonable assessment on existing problems was made and possible solutions to the problems were proposed. 
RESULTS: As a new imaging diagnostic technique, the contrast-enhanced ultrasound, which can enhance the display of tumor microcirculation vessels and improve the tumor’s ultrasound diagnostic capability, was analyzed. Through sorting and comprehensively analyzing the collected literatures, the positive rate of ocular spaceoccupying lesion diagnosis could be significantly improved with ultrasound contrast technology. Thus, the vascular perfusion in normal tissues and lesions was reflected objectively. According to the lesion’s perfusion characteristics of the contrast agent plus with the performance features of two-dimensional ultrasound, the ocular spaceoccupying lesions can be accurately diagnosed, and this could provide clinicians with reliable research basis in this field.
CONCLUSION: Ultrasound contrast examination is a new testing method, and ultrasound contrast agent can significantly enhance the ultrasonic detection signal, clearly show the blood perfusion in vessels and tissues, increase the image contrast resolution, and improve the lesion’s detection capability in the microcirculation perfusion level, especially its important value in the diagnosis of ocular tumor.
]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Jia-Ying Yuan,Jian-Hua Zhang,Chong Tang,Jing-Zhi Zhao,Chao Pang,Xin-Chun Ren,Hong Zhu and Yun-Tao Zhang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Jia-Ying Yuan,Jian-Hua Zhang,Chong Tang,Jing-Zhi Zhao,Chao Pang,Xin-Chun Ren,Hong Zhu and Yun-Tao Zhang</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201104002]]></guid><cfi:id>31</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Surgical treatment for primary angle closure-glaucoma: a Meta analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201103001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM:To evaluate the efficacy and safety of trabeculectomy, phacotrabeculectomy plus intraocular lens implantation(phacotrab+IOL group) and phacoemulsification with IOL(phaco+IOL) in primary angle-closure glaucoma(PACG). 
METHODS: It was a systematic review and meta-analysis, randomized controlled trials(RCT) and clinical controlled trials(CCT) were collected through electronic searches of the Cochrane Library, PubMed, EMbase, Wanfang Database online, Chinese journal Full-text Database, Chinese Scientific Journals Full-text Database (from the date of building the database to October 2010) We also checked the bibliographies of retrieved articles. All the related data that matched our standards were abstracted. The quality of included trials was evaluated according to the Dutch Cochrane Centre. RevMan 5.0 software was used for Meta-analysis.
RESULTS: A total of 5 RCT and 11 CCT involving 1495 eyes were included. The results of meta-analysis showed that phacotrab+IOL group was superior than trabeculectomy(trab group) (MD -3.93,95%CI [-7.31, -0.54]) which was also superior than phaco+IOL group(MD 0.52,95%CI [0.10, 0.95]) in decreasing Intraocular Pressure(IOP). Phacotrab group(MD -1.45,95%CI [-1.68, -1.22])and phaco group (MD-1.12,95%CI [-1.87, -0.37])are both deeper than trab group in the anterior chamber depth. In increasing the coefficient of outflow facility of aqueous humor(C values) there was no statistical difference in the three groups. And there was no statistical difference between phacotrab groups and phaco groups in visual acuity but phacotrab group was superior than phaco group (MD 1.07, 95%CI [0.73, 1.40])in the use of IOP-lowering drugs. There was no statistical difference among three groups. 
CONCLUSION: Current evidence suggests that phacotrab+ IOL group was superior than trab group which was also superior than phaco+IOL group in decreasing IOP. Phacotrab group and phaco group are both deeper than trab group in the anterior chamber depth. Phacotrab group was superior than phaco group in the use of IOP-lowering drugs.
]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Bo-Lin Deng,Cheng Jiang,Bin Ma,Wen-Fang Zhang,Peng Lü,Yuan-Yuan Du,Xu-Dong Jiu,Le-Xin Yang and Jing Tian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Bo-Lin Deng,Cheng Jiang,Bin Ma,Wen-Fang Zhang,Peng Lü,Yuan-Yuan Du,Xu-Dong Jiu,Le-Xin Yang and Jing Tian</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201103001]]></guid><cfi:id>30</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Establishment of an untransfected human corneal epithelial cell line and its biocompatibility with denuded amniotic membrane]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201103002]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To establish an untransfected human corneal epithelial (HCEP) cell line and characterize its biocompatibility with denuded amniotic membrane (dAM).
METHODS: The torn HCEP pieces were primarily cultured in DMEM/F12 media (pH 7.2) supplemented with 20% fetal bovine serum and other necessary factors, yielding an HCEP cell line which was its growth performance, chromosome morphology, tumorigenicity and expression of marker proteins analyzed. In addition, the biocompatibility of HCEP cells with dAM was evaluated through histological and immunocytochemistry analyses and with light, electron and slit-lamp microscopies.
RESULTS: HCEP cells proliferated to confluence in 3 weeks, which have been subcultured to passage 160. A continuous untransfected HCEP cell line, designated as utHCEPC01, was established with a population doubling time of 45.42 hours as was determined at passage 100. The cells retained HCEP cell properties as were approved by chromosomal morphology and the expression of keratin 3. They, with no tumorigenicity, formed a multilayer epithelium-like structure on dAMs through proliferation and differentiation during air-liquid interface culture, maintained expression of marker proteins including keratin 3 and integrin β1 and attached tightly to dAMs. The reconstructed HCEP was highly transparent and morphologically and structurally similar to the original.
CONCLUSION: An untransfected and non-tumorigenic HCEP cell line was established in this study. The cells maintained expression of marker proteins. The cell line was biocompatible with dAM. It holds the potential of being used for in vitro reconstruction of tissue-engineered HCEP, promising for the treatment of diseases caused by corneal epithelial disorders.
]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Ting-Jun Fan,Bin Xu,Jun Zhao,Hong-Shou Yang,Rui-Xin Wang and Xiu-Zhong Hu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Ting-Jun Fan,Bin Xu,Jun Zhao,Hong-Shou Yang,Rui-Xin Wang and Xiu-Zhong Hu</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201103002]]></guid><cfi:id>29</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Bibliometric analysis on retinoblastoma literatures in PubMed during 1929 to 2010]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201102001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To determine the growth rule and tendency of retinoblastoma (Rb) literature, and to provide the basis for research of diagnosis, treatment and  on Rb.
METHODS: Bibliometric analyses were carried out on Rb literatures which contain the descriptors of Rb in their titles or texts from 1929 to 2010 in PubMed database (www.ncbi.nlm.nih.gov/Pubmed). The biomedical journals referring to Rb by using bibliometric indicators were calculated. The principal bibliometric indicators, i.e., Price's and Bradford's laws to the increase or distribution of scientific literature, the participation index of languages and the journals were applied. By means of manual coding, Rb documents were classified according to documents studied and to statistical analysis. 
RESULTS: During 1929-2010, there were 16162 literatures in the PubMed database including the word Rb. According to the literature type, it includes Review (n=2026), Randomized Controlled Trial (n=7), Practice guideline (n=3), meta- analysis (n=4), letter (n=215), editorial (n=98), clinical trial (n=115) and others (n=13694). By the statistical analysis, its equation is near power index (y=3.0477x 2.6088, R2= 0.9666). From 1929 to 2010, Rb literatures in English were primarily dominant (90.71%) and the amount of the literature in Chinese ranked the fourth (1.37%). By searching PubMed, 1420(8.8%) literatures covered were from 41 of 48 ophthalmological, and 406 (2.5%) literatures from 44 of 86 pediatrics journals that correlated with retinoblastoma (SCI-indexed). The data showed that the literatures of Rb were gradually increasing year by year and were approximate near power index during 1929-2010, and the document publishes published mainly in ophthalmological journals, and in English (90.71%), and showing that the study on Rb is a popular subject in the last half century.
CONCLUSION: The literatures of Rb are gradually increasing, mainly English in ophthalmologic journals.
]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Zhi-Guang Zhao,Xue-Gang Guo,Chang-Tai Xu,Bo-Rong Pan and Li-Xian Xu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Zhi-Guang Zhao,Xue-Gang Guo,Chang-Tai Xu,Bo-Rong Pan and Li-Xian Xu</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201102001]]></guid><cfi:id>28</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Current gamma knife treatment for ophthalmic branch of primary trigeminal neuralgia]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201102002]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To probe into problems existing in gamma knife treatment of ophthalmic branch of primary trigeminal neuralgia (TN), and propose a safe and effective solution to the problem.
METHODS: Through sorting the literature reporting gamma knife treatment of refractory TN in recent years, this article analyzed the advantages and problems of gamma knife treatment of primary TN, and proposed reasonable assessment for existing problems and the possible solution.
RESULTS: Gamma knife treatment of TN has drawn increasing attention of clinicians due to its unique non-invasion, safety and effectiveness, but there are three related issues to be considered. The first one is the uncertainty of the optimal dose (70-90GY); the second one is the difference in radiotherapy target selection (using a single isocenter or two isocenters); and the third one is the big difference of recurrent pains (specific treatment methods need to be summarized and improved). 
CONCLUSION: For patients with refractory TN, gamma knife treatment can be selected when the medical treatment fails or drug side effects emerge. The analysis of a large number of TN patients receiving gamma knife treatment has shown that this is a safe and effective treatment method.
]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Guo-Yong Shan,Hao-Fang Liang and Jian-Hua Zhang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Guo-Yong Shan,Hao-Fang Liang and Jian-Hua Zhang</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201102002]]></guid><cfi:id>27</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Development of biomedical publications on ametropia research in PubMed from 1845 to 2010: a bibliometric analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201101001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: We have carried out a bibliometric analysis on the development of ametropia literature to determine its growth rule and tendency, and to provide the basis for the problems related to ametropia research. 
METHODS: Literatures that contained the descriptors of ametropia in title or paper published before Nov. 10, 2010 in PubMed databases (www.ncbi.nlm.nih.gov/Pubmed) were selected. As bibliometric indicators of ametropia, biomedical journals referring to ophthalmology by ISSN were calculated. The principal bibliometric indicators: Price's and Bradford's laws were applied on the increase or dispersion of scientific literature, the participation index of languages and the journals. By means of manual coding, literatures were classified according to documents study and statistical analysis. 
RESULTS: The literatures cited in ametropia, astigmatism, myopia and hypermetropia had accumulated to 26475, which consists of Review (n=1560), Randomized Controlled Trial (n=776), Practice Guideline (n=10), Meta-Analysis (n=23), Letter (n=1222), Editorial (n=328), Clinical Trial (n=1726) and Others (n=20830), and Humans (n=23073), Animals(n=1434) and others (n=1968). 1136 literatures were included in PubMed Central, 22384 in MEDLINE and 2955 in others. The ametropia literatures rose every 5 years which of the ametropia-year cumulated amount of the literatures had three periods: before 1900, slowly increasing from 1901 to 1950, rapidly rising from 1951 to 2010 (increased approximate exponentiation exponent). Sixty kinds of languages listed in PubMed databases, of which English is dominant for aborting to ametropia research documents before 2010 (77.32%, 20471/26475). The document languages of top eight account for 95.58% (English, German, French, Japanese, Russian, Italian, Spanish, Chinese), and others for 4.42% (1171/26475). The SCI database includes 48 ophthalmologic journals and the impact factor of 39 journals is ≥1 on Thomson-Reuters in 2010. Of 48 ophthalmologic journals, there were 14785 documents (55.85%) of ametropia, astigmatism, myopia, and hypermetropia. Others were without exception. 
CONCLUSION: The bibliometric analysis results show that ametropia literature are increased progressively, approximate exponentiation exponent during 1951-2010. In addition, ametropia research has become more popular since nearly half century.
]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Chang-Tai Xu,Shan-Qu Li,Yong-Gang Lü and Bo-Rong Pan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Chang-Tai Xu,Shan-Qu Li,Yong-Gang Lü and Bo-Rong Pan</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201101001]]></guid><cfi:id>26</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Bioinformatics-led design of single-chain antibody molecules targeting DNA sequences for retinoblastoma]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201101002]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To analyze the relationship between the structure and function of single-chain Fv antibody (scFv) with bioinformatics methods, so as to provide theoretical basis for retinoblastoma targeted therapy. 
METHODS: Single-chain antibodies are reconstructed for cancer-targeted therapy to provide good penetration into tumor tissue and to improve their pharmacokinetics in vivo, offering a clinically valuable application. The relationship needs to be analyzed that there may be some variations between the structure and function of the fusion proteins, and the relationship between the structure and function of protein molecules was obtained through analyzing relevant literature at home and abroad as well as modeling analysis. 
RESULTS: Through our analysis of the interaction region between the antibody and the antigen, and of the binding sites for molecular conformation, it is clear that existing antibodies need to be modified at the DNA sequence level, enhancing the biological activity of the antibodies. Based on the view that bio-molecular computer models are closely integrated with biological experiments, a bio-molecular structure–activity relationship model can be established in terms of molecular conformation, physical and chemical properties and the biological activity of single-chain antibodies. Two enlightenments are obtained from our analysis. On the one hand, the structure–activity relationship is clear for new immune molecules at the gene expression level. On the other hand, a single-chain antibody molecule can be designed and optimized for the cancer-oriented treatment. 
CONCLUSION: In this article, we provide the theoretical and experimental basis for the development of single-chain antibodies appropriate for retinoblastoma therapy. 
]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Guo-Gang Shang,Jian-Hua Zhang,Yong-Gang Lu and Jun Yun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Guo-Gang Shang,Jian-Hua Zhang,Yong-Gang Lu and Jun Yun</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201101002]]></guid><cfi:id>25</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Meta analysis on the relationship between gene polymorphisms of vascular endothelial growth factor and retinal prognosis risk of prematurity]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201203029]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To explore the relationship between gene polymorphisms of vascular endothelial growth factor (VEGF) and retinopathy of prematurity (ROP). 
METHODS: Literature materials related to gene polymorphisms of VEGF and ROP in PubMed, EMBASE, Cochrane and CBM database were retrieved. These materials were screened according to inclusion and exclusion standards. Patients diagnosed with ROP in clinic were regarded as control group and ROP patients who were in treatment were regarded as observation group. The indexes in two groups were matched except birth weight (BW), gender and gestational weeks. Meta5.1 was used to analyze the relationship between gene polymorphisms of VEGF and ROP. 
RESULTS: Four random control tests (RCT) were included in this research, including 2611 patients. Meta analysis results showed that VEGF affected ROP, having statistical significance. The combined ratio was 0.44 (95%CI, 0.07, 0.80), 0.42 (95%CI, 0.09, 0.74) and 0.75 (95%CI, 0.02, 1.49), respectively. Carrying +405 allele might increase the premature infants’ risk of having ROP. 
CONCLUSION: ROP may be related to its carrying of +405 allele. Large-scale, multi-factor RCT researches are still needed in order to identify the relation between VEGF and ROP.]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Jun Zhai,Qiu-Hui Jiang,Chun-Xi Liu,Zuo-Rong Tian and Ying-Pu Sun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Jun Zhai,Qiu-Hui Jiang,Chun-Xi Liu,Zuo-Rong Tian and Ying-Pu Sun</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201203029]]></guid><cfi:id>24</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Optical coherence tomography assessed retinal nerve fiber layer thickness in patients with Alzheimer’s disease: a meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201203030]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To investigate the difference of retinal nerve fiber layer (RNFL) thickness between Alzheimer’s disease patients and normal people, so as to provide clue for the early diagnosis of Alzheimer’s disease. 
METHODS: The articles on the association of RNFL thickness and Alzheimer’s disease were retrieved by searching international and national databases. The qualified articles were assessed by meta analysis with Stata11.0 software. The results were pooled using weighted mean difference (WMD) with a corresponding 95% confidence interval (CI).
RESULTS: Totally 7 studies enrolled 324 eyes were included in the meta-analysis. The results of meta analysis showed that in AD patients, there was a significant average RNFL thickness reduction compared with the control group [WMD=-17.561, 95%CI: (-23.971, -11.151)]. There were significant differences in superior, inferior, nasal and temporal RNFL thickness between the two groups. WMD with a 95%CI were [-18.829, 95%CI:(-25.915, -11.743); P<0.05], [-25.775, 95%CI:(-34.304, -17.247); P<0.05], [-16.877, 95%CI: (-29.141, -4.613); P<0.001] and [-14.565, 95%CI:(-28.002, -1.128); P<0.001] respectively. Begg’s test and Egger’s test did not show significant difference, funnel plot was basically symmetrical, indicating that there was no publication bias existed.
CONCLUSION: There are significant differences in the RNFL thickness in all quadrants between the two groups. RNFL thickness is reduced in AD patients compared with the control group.]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Xue-Fei He,Yi-Ting Liu,Cheng Peng,Fan Zhang,Shi Zhuang and Jin-Song Zhang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Xue-Fei He,Yi-Ting Liu,Cheng Peng,Fan Zhang,Shi Zhuang and Jin-Song Zhang</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201203030]]></guid><cfi:id>23</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Association between complementary factor H Y402H polymorphisms and age-related macular degeneration in Chinese: Systematic review and meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201202025]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and complement factor H (CFH) polymorphism has been found to associate with the AMD. To investigate whether the Y402H variant in CFH is associated with AMD in Chinese populations, a systematic review and meta-analysis were performed to estimate the magnitude of the gene effect and the possible mode of action. 
 METHODS: A meta-analysis was performed using data available from ten case-control studies assessing association between the CFH Y402H polymorphism and AMD in Chinese populations involving 1538 AMD. Data extraction and study quality assessment were performed in duplicate. Summary odds ratios (ORs) and 95% con?dence intervals (CIs) an allele contrast and genotype contrast were estimated using ?xed- effects models. The Q-statistic test was used to assess heterogeneity, and Funnel plot was used to evaluate publication bias.
 RESULTS: Seven of ten case-control studies were neovascular AMD, and few studies came from west and north of China. There was strong evidence for association between CFH and AMD in Chinese population, with those having risk allele C 2.35 times more likely to have AMD than subjects with T allele. Evidence of publication bias was not observed in our meta-analysis. 
 CONCLUTION: This meta-analysis summarizes the strong evidence for an association between CFH and AMD in Chinese and indicates each C allele increasing the odds of AMD by 2.33-fold.But more evidences about the relation between CFH polymorphism and different type of Chinese AMD from various district were needed.]]></description>
<pubDate></pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Yan-Long Quan,Ai-Yi Zhou and Zhao-Hui Feng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yan-Long Quan,Ai-Yi Zhou and Zhao-Hui Feng</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/201202025]]></guid><cfi:id>22</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Complement factor B polymorphism (rs641153) and susceptibility to age-related macular degeneration:evidence from published studies]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20130621]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b>To determine whether single nucleotide polymorphism (SNP) rs641153 is associated with the risk of age-related macular degeneration (AMD), we performed a systematic meta-analysis of 15 eligible studies. SNP in the complement factor B (CFB) gene is considered to have significant association with AMD susceptibility, but there is great discrepancy in these results.<b>METHODS:</b> The eligible studies were identified by searching the databases of PubMed, EMBASE, and Web of Science. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association. All data were analyzed using Stata software.<b>RESULTS:</b>The association between rs641153 and AMD risk was statistically significant under the homozygous model (AA <i>vs </i>GG:OR=0.26, 95%CI=0.15-0.45, <i>P</i>h<i>=</i>0.973, <i>I</i><sup>2</sup>=0.0%, fixed effects), dominant model (AA+GA <i>vs </i>GG:OR=0.49, 95%CI=0.40-0.59, <i>P</i>h<i>=</i>0.004, <i>I</i><sup>2</sup>=56.4%, random effects) and recessive model (AA <i>vs</i> GA+GG:OR=0.30, 95%CI=0.17-0.51, <i>P</i>h<i>=</i>0.983, <i>I</i><sup>2</sup>=0.0%, fixed effects). The same results were also observed in the stratified analyses by ethnicity, source of control and sample size.<b>CONCLUSION:</b>Our meta-analysis suggests that rs641153 in the CFB gene may play a protective role in AMD susceptibility, the late AMD in particular, both in Caucasians and in Asians.]]></description>
<pubDate>2013/12/22 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Xin Wang,Ying Zhang and Mao-Nian Zhang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Xin Wang,Ying Zhang and Mao-Nian Zhang</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20130621]]></guid><cfi:id>21</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Visual function and higher order aberration after implantation of aspheric and spherical multifocal intraocular lenses:a meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20130528]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To assess the visual outcomes of aspheric multifocal intraocular lenses (IOLs) compared with spherical multifocal IOL after cataract surgery.<b>METHODS</b>:Potential prospective controlled trials that comparing aspheric multifocal IOL implantation with spherical multifocal IOL group were extracted from the computer database. The statistical analysis was carried out using Stata 10 software. Standardized mean differences with 95% confidence intervals (CIs) were calculated for continuous variables. The pooled estimates were computed in the use of a random-effects model.<b>RESULTS</b>:A systematic review identified five prospective nonrandomized controlled trials, including 178 aspheric multifocal IOL and 164 spherical multifocal IOL. There was no significant difference in uncorrected distance visual acuity (95%CI, -0.248 to 0.152;<i>P</i>=0.641) and uncorrected near visual acuity (95%CI, -0.210 to 0.428;<i>P</i>=0.504) between aspheric multifocal IOL and spherical multifocal IOL. Statistically significant differences were detected less spherical aberration in aspheric multifocal IOL (95%CI, -1.111 to -0.472; <i>P</i>＜0.001) when compared to spherical multifocal IOL. Spherical multifocal IOL showed a greater higher order aberration  compared to the aspheric multifocal IOL (95%CI, -1.024 to-0.293; <i>P</i>＜0.001). Sensitivity analysis suggested that the results were relatively reliable.<b>CONCLUSION</b>:The overall findings indicated that aspheric multifocal IOL and spherical multifocal IOL provided similar visual acuity at near and distance. Patients implanted with aspheric multifocal IOL had less spherical aberration and higher order aberration than patients with spherical multifocal IOL. Further well-organized, prospective controlled trials involving larger patient numbers are needed.]]></description>
<pubDate>2013/10/21 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Jian-Ping Liu,Fan Zhang,Jiang- Yue Zhao,Li-Wei Ma and Jin-Song Zhang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Jian-Ping Liu,Fan Zhang,Jiang- Yue Zhao,Li-Wei Ma and Jin-Song Zhang</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20130528]]></guid><cfi:id>20</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Association between lumican gene -1554 T/C polymorphism and high myopia in Asian population:a meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20130529]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b>To investigate the association between lumican gene -1554 T/C polymorphism and high myopiasusceptibility.<b>METHODS:</b> We searched the published literature in the Medline, Embase, and CBM databases from inception to July 2013. A meta-analysis was performed by the programs RevMan 5.1 and Stata 12.0, and the odds ratio (OR) with 95% confidence interval (CI) was calculated in fixed or random effect model based on  heterogeneity test among studies.<b>RESLUTS:</b>Seven case-control studies with a total of 1 233 cases and 936 controls were included. A statistical significant association with high myopia was observed in the recessive model (TT <i>vs</i> CT+CC:OR=1.92; 95%CI=1.14-3.23) and codominant model (TT <i>vs</i> CT:OR=1.81, 95%CI=1.19-2.75).<b>CONCLUSION:</b> The present meta-analysis suggested that lumican -1554 T/C polymorphism might be moderately associated with high myopia susceptibility. This conclusion warrants confirmation by further studies.]]></description>
<pubDate>2013/10/21 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Xuan Liao,Xu-Bo Yang,Meng Liao,Chang-Jun Lan and Long-Qian Liu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Xuan Liao,Xu-Bo Yang,Meng Liao,Chang-Jun Lan and Long-Qian Liu</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20130529]]></guid><cfi:id>19</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema:a meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20130426]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To compare the efficacy of the sole intravitreal triamcinolone (IVT) versus intravitreal bevacizumab (IVB) alone or IVB combined with IVT in the treatment of diabetic macular edema (DME).<b>METHODS:</b> Pertinent publications were identified through systematic searches of database and manually searching. Methodological quality of the literatures was valuated according to the Jadad Score. RevMan 5.1.0 was used to do the meta-analysis. Heterogeneity was determined and sensitivity was conducted.<b>RESULTS:</b> Six studies were ultimately included in the meta-analysis. The results of our analysis showed IVT had a statistically significant improvement in vision over the IVB at 1 month and 3 months (<i>P</i>＜0.01＝. However, the reduction was not significant regarding central macular thickness (CMT) during the earlier (1 month and 3 months) follow-up period (<i>P</i>=0.12, <i>P</i>=0.41, respectively). At later visit (6 months), IVT had a significant decrease in CMT when compared to IVB (<i>P</i>＜0.01) while no significant improvement in visual acuity (VA) was observed (<i>P</i>=0.14). The incidence of intraocular hypertension was 13/102 in IVT group during follow-up period while 0/103 in IVB group. The difference was significant (<i>P</i>＜0.01). With regards to IVT versus IVB combined with IVT, there were no significant differences in CMT at 1 month (<i>P</i>=0.86) and 3 months (<i>P</i>=0.06). The incidence of intraocular hypertension was 6/67 in IVT group during follow-up period while 4/66 in IVB+IVT group. But the difference was not significant (<i>P</i>=0.53).<b>CONCLUSION:</b>Current evidence shows IVT is superior in improving VA at earlier follow-up (1 month and 3 months) and in reducing CMT at later follow-up (6 months) for DME. At other time, it is in favor of IVT treatment but there are no statistically significances. However, IVT has the side-effect of ocular hypertension. There is no adequate evidence of the benefit adding IVB to IVT in contrast to IVT alone.]]></description>
<pubDate>2013/8/22 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Xiao-Ling Zhang,Jian Chen,Ri-Jia Zhang,Wen-Jie Wang,Qing Zhou and Xiao-Yan Qin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Xiao-Ling Zhang,Jian Chen,Ri-Jia Zhang,Wen-Jie Wang,Qing Zhou and Xiao-Yan Qin</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20130426]]></guid><cfi:id>18</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema:a systemic review and Meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140626]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To further evaluate the efficacy and safety of intravitreal bevacizumab (IVB) versus macular photocoagulation (MPC) in treatment of diabetic macular edema (DME) by Meta-analysis.<b>METHODS:</b> Pertinent publications were identified through systemic searches of PubMed, Medline, EMBASE, and the Cochrane Controlled Trials Register up to 30 November, 2013. Changes in central macular thickness (CMT) in μm and best-corrected visual acuity (BCVA) in logMAR equivalents were extracted at 1, 3, 6, 12 and 24mo after initial treatment, and a Meta-analysis was carried out to compare results between groups receiving IVB and MPC.<b>RESULTS:</b>Five randomized controlled trial (RCTs) and one high-quality comparative study were identified and included. Our Meta-analysis revealed that both IVB and MPC resulted in the improvements of CMT and BCVA in eyes with DME at 1mo after initial treatment, with IVB being significantly superior to MPC (<i>P</i>=0.01 and 0.02, respectively). The improvements of both measure outcomes at 3, 6, 12 and 24mo after treatment did not vary significantly between the IVB groups and MPC groups (CMT at 3mo, <i>P</i>=0.85; at 6mo, <i>P</i>=0.29; at 12mo, <i>P</i>=0.56; at 24mo, <i>P</i>=0.71; BCVA at 3mo, <i>P</i>=0.31; at 6mo, <i>P</i>= 0.30; at 12mo, <i>P</i>=0.23; at 24mo, <i>P</i>=0.52). However, the number of observed adverse events was low in all studies.<b>CONCLUSION:</b> Current evidence shows IVB treatment trends to be more effective in improvements of macular edema and vision in eyes with DME at an earlier follow up (1mo) compared with MPC. At other time, both interventions have comparable efficacy without statistical significances.]]></description>
<pubDate>2014/12/15 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Xiang-Dong Liu,Xiao-Dong Zhou,Zhi Wang and Hong-Jie Shen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Xiang-Dong Liu,Xiao-Dong Zhou,Zhi Wang and Hong-Jie Shen</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140626]]></guid><cfi:id>17</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Iris color and associated pathological ocular complications:a review of epidemiologic studies]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140525]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b>To elucidate the associations of iris color with major eye diseases.<b>METHODS:</b>A systematic search on Medline with coverage up to August 2013 was conducted. Assessment of the quality of studies based on their levels of evidence was in accordance with the Centre for Evidence-Based Medicine, Oxford, United Kingdom.<b>RESULTS:</b>A relationship between darker iris color and an increased risk of age-related cataract has been reported from cross-sectional studies and prospective cohort studies. There was no consistent evidence supporting a major role of iris color in the development or progression of age-related macular degeneration. The association of iris color with ocular uveal melanoma has been confirmed by a meta-analysis of observational studies previously. The etiologic synergism between light iris color and environmental exposure such as UV the exposure of UV radiation was found. There were no studies evaluating the refractive associations with iris color but there may be a possible link between iris color and myopia.<b>CONCLUSION:</b>Darker iris color is associated with an increased risk of cataractand a reduced risk ofocular uveal melanoma. The association of iris color with age-related macular degeneration is not confirmed. Ophthalmologists should be aware that the risk of ocular disorders appears to vary by differences in iris color.]]></description>
<pubDate>2014/10/20 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Hong-Peng Sun,Yi Lin and Chen-Wei Pan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Hong-Peng Sun,Yi Lin and Chen-Wei Pan</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140525]]></guid><cfi:id>16</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension:a systematic review and meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140526]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b>To assess the effects of the fixed combination of 0.005% latanoprost and 0.5% timolol (FCLT) <i>vs</i> their individual components for primary open angle glaucoma (POAG) and ocular hypertension (OHT).<b>METHODS:</b>After searched PubMed, EMBASE, the Cochrane Library and SCI, all randomized controlled clinical trials (RCTs) and cross-over studies were included. The control groups were the mono therapy or the concomitant therapy of latanoprost and timolol. The outcomes were visual field defect, optic atrophy, mean intraocular pressure (IOP) and IOP fluctuation. The analysis was carried out in RevMan version 5.1 software.<b>RESULTS:</b>The post-intervention mean IOP of FCLT was significantly lower compared to timolol [mean difference (MD) -2.92, 95%CI -3.28 to -2.55, <i>P</i>&lt;0.00001] and latanoprost (MD -1.11, 95%CI -1.51 to -0.72, <i>P</i>＜0.00001). The post-intervention IOP fluctuation was also significantly lower compared to timolol (MD -0.88, 95%CI -1.23 to -0.53, <i>P&lt;</i>0.00001) and latanoprost (MD -0.63, 95%CI -1.04 to -0.22, <i>P=</i>0.002). The mean IOP was higher in FCLT morning dose group than the one in unfixed combination of 0.005% latanoprost and 0.5% timolol (UFCLT) (MD 1.10, 95%CI 0.81 to 1.39, <i>P&lt;</i>0.00001). Otherwise, there was no difference between FCLT evening dose group and UFCLT (MD 0.34, 95% CI -0.01 to 0.69, <i>P=</i>0.06). There was no statistical difference for the incidence of visual field defect and optic atrophy between FCLT and the monotherapy of components.<b>CONCLUSION:</b>A better IOP lowering effect has been demonstrated for FCLT compared to the mono therapy of components. The IOP lowering effect was worse for FCLT morning dose and almost same for FCLT evening dose compared to the UFCLT. We need more long-term high quality RCTs to demonstrate the outcomes of visual field defect and optic atrophy.]]></description>
<pubDate>2014/10/20 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Yi Xing,Fa-Gang Jiang and Teng Li]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yi Xing,Fa-Gang Jiang and Teng Li</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140526]]></guid><cfi:id>15</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Meta-analysis of best corrected visual acuity after treatment for myopic choroidal neovascularisation]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140425]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To compare the best corrected visual acuity (BCVA) between Verteporfin with photodynamic therapy (PDT) and intravitreal anti-vascular endothelial growth factor (anti-VEGF) in patients with myopic choroidal neovascularization (CNV).<b>METHOD:</b> Published literature from Medline, Premedline, Embase and the Cochrane Library from inception until November 2013 were retrieved. All studies evaluating the BCVA between Verteporfin with PDT and intravitreal anti-VEGF for myopic CNV were included. The results were pooled using mean difference (MD), a corresponding 95% confidence interval (CI).
<b>RESULTS:</b>Finally, five studies enrolled 349 eyes were included in the meta-analysis. We inferred that the BCVA of myopic CNV after the treatment of anti-VEGF was significantly better compared with Verteporfin with PDT (MD=0.25, 95％CI:0.17-0.33, <i>Z</i>=5.97, <i>P</i>&lt;0.00001).
<b>CONCLUSION:</b> This meta-analysis suggests that intravitreal anti-VEGF could have a better BCVA after treatment than Verteporfin with PDT for myopic CNV.]]></description>
<pubDate>2014/8/15 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Lin Zhou,Yi-Qiao Xing,Tuo Li,Yin Li,Xiu-Sheng Song and Jia-Zhang Li]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Lin Zhou,Yi-Qiao Xing,Tuo Li,Yin Li,Xiu-Sheng Song and Jia-Zhang Li</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140425]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration:a systematic review and meta-analysis of randomized controlled trials]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140328]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM</b>:To compare the efficacy and safety of combination of ranibizumab with photodynamic therapy (PDT) <i>vs</i> ranibizumab monotherapy in the treatment of age-related macular degeneration (AMD).<b>METHODS</b>:The Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, Pubmed, and Embase were searched. There were no language or data restrictions in the search for trials. Only randomized controlled trials (RCTs) were included. Methodological quality of the literatures was evaluated according to the Jadad Score. RevMan 5.2.6 software was used to do the meta-analysis.<b>RESULTS:</b>Seven studies were included in our systematic review, among which four of them were included in quantitative analysis. The result shows that the ranibizumab monotherapy group had a better mean best corrected visual acuity (BCVA) change <i>vs</i> baseline at month 12 compared with that of the combination treatment group, and the statistical difference was significant (WMD, -2.61; 95% CI, -5.08 to -0.13; <i>P=</i>0.04). However, after the removal of one study, the difference between the two groups showed no significant difference (WMD, -2.29; 95% CI, -4.81 to 0.23; <i>P=</i>0.07). Meanwhile, no significant central retinal thickness (CRT) reduction was found in the combination treatment group and the ranibizumab monotherapy group at 12 months follow-up. Nevertheless, the combination group tended to have a greater reduction in CRT (WMD, -4.13μm; 95%CI, -25.88 to 17.63, <i>P=</i>0.71). The proportion of patients gaining more than 3 lines at month 12 in the ranibizumab group was higher than in the combination group and there was a significant difference (RR, 0.72; 95% CI, 0.54 to 0.95; <i>P=</i>0.02). Whereas there was no significant difference for the proportion of patients gaining more than 0 line at month 12 between the two groups (RR, 0.93; 95% CI, 0.76 to 1.15; <i>P=</i>0.52). The general tendency shows a reduction in ranibizumab retreatment number in the combination treatment group compared with the ranibizumab monotherapy group. As major adverse events, the differences in the number of eye pain, endophthalmitis, hypertension and arterial thromboembolic events were not significant between the two groups, and the incidence of serious adverse events in the two groups was very low.<b>CONCLUSION</b>:For the maintenance of vision, the comparison of the combination of ranibizumab with PDT <i>vs</i> ranibizumab monotherapy shows no apparent difference. Compared with the combination of ranibizumab and PDT, patients treated with ranibizumab monothearpy may gain more visual acuity (VA) improvement. The combination treatment group had a tendency to reduce the number of ranibizumab retreatment. Both the two treatment strategies were well tolerated.]]></description>
<pubDate>2014/6/24 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Jun-Kang Si,Kai Tang,Hong-Sheng Bi,Da-Dong Guo,Jun-Guo Guo,Yu-Xiang Du,Yan Cui,Xue-Mei Pan,Ying Wen and Xing-Rong Wang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Jun-Kang Si,Kai Tang,Hong-Sheng Bi,Da-Dong Guo,Jun-Guo Guo,Yu-Xiang Du,Yan Cui,Xue-Mei Pan,Ying Wen and Xing-Rong Wang</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140328]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Lack of association between lysyl oxidase-like 1 polymorphisms and primary open angle glaucoma:a meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140329]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To study the associations between <i>lysyl oxidase-like 1</i> (<i>LOXL1</i>) polymorphisms and primary open angle glaucoma (POAG) remain inconsistent. In this study, we have performed a meta-analysis to investigate the association of <i>LOXL1</i> polymorphisms with POAG risk.<b>METHODS:</b> Published literature from PubMed and other databases were retrieved. All studies evaluating the association between <i>LOXL1</i> polymorphisms (rs2165241, rs1048661, rs3825942) and POAG risk were included. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using random- or fixed-effects model.<b>RESULTS:</b> Twelve studies were identified as eligible articles, with thirteen (2098 cases and 16 473 controls), thirteen (1795 cases and 2916 controls) and sixteen population cohorts (2456 cases and 2846 controls) for the association of rs2165241, rs1048661 and rs3825942 with POAG risk respectively. Overall analyses showed no association between each <i>LOXL1</i> polymorphism and POAG risk, and the negative associations were remained when the subjects were stratified as Caucasian and Asian. The heterozygote of rs2165241 was associated with reduced POAG risk in hospital-based populations (TC <i>vs</i> CC:OR, 0.79, 95%CI:0.63-0.99), and rs1048661 was associated with increased POAG risk in hospital-based populations in a dominant model (TT <i>vs</i> CC+CT:OR, 1.23, 95%CI:1.01-1.50); however, these associations were not found in population-based subjects.<b>CONCLUSION:</b> This meta-analysis suggests that <i>LOXL1 </i>polymorphisms are not associated with POAG risk. Given the limited sample size, the associations of <i>LOXL1 </i>polymorphisms with POAG risk in hospital-based populations await further investigation.]]></description>
<pubDate>2014/6/24 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Wen Sun,Yan Sheng,Yu Weng,Chun-Xiao Xu,Susan E.I. Williams,Yu-Tao Liu,Michael A. Hauser,R. Rand Allingham,Ming-Juan Jin and Guang-Di Chen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Wen Sun,Yan Sheng,Yu Weng,Chun-Xiao Xu,Susan E.I. Williams,Yu-Tao Liu,Michael A. Hauser,R. Rand Allingham,Ming-Juan Jin and Guang-Di Chen</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140329]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140230]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To compare the effectiveness and safety between bevacizumab and ranibizumab in the treatment of age-related macular degeneration (AMD) through a systematic review and meta-analysis.<b>METHODS:</b>We performed a comprehensive search of randomized controlled trials (RCTs), non-RCTs, case-control and cohort studies that compared bevacizumab and ranibizumab using PubMed and the Cochrane Library. After the related data were extracted by two investigators independently, pooled weighted mean differences (WMDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects or a fixed-effects model.<b>RESULTS:</b>A total of four RCTs involving 1927 patients and eleven retrospective case series involving 2296 patients were included. For the primary outcomes, no significant differences were found between ranibizumab group and bevacizumab group in visual acuity (WMD:-0.04; 95%CI:-0.08 to 0.00; <i>P=</i>0.06), best corrected visual acuity (WMD:-0.05; 95%CI:-0.10 to 0.00; <i>P=</i>0.05), retina thickness (WMD:-4.69; 95%CI:-13.15 to 3.76; <i>P=</i>0.86) and foveal thickness (WMD:10.91; 95%CI:-14.73 to 36.56; <i>P=</i>0.40). The pooled analyses in the evaluation of safety showed that compared to bevacizumab, ranibizumab was associated with decreased risks of ocular inflammation (RR:0.45; 95% CI:0.23 to 0.89; <i>P=</i>0.02) and venous thrombotic events (RR:0.27; 95%CI:0.08 to 0.89; <i>P=</i>0.03). However, there were no significant differences observed in deaths (<i>P=</i>0.69) and arterial thromboembolic events (<i>P=</i>0.71) between the two groups.<b>CONCLUSION:</b>With equal clinical efficacy, ranibizumab was found to be associated with less adverse events compared to bevacizumab, indicating that ranibizumab might be a safer management.]]></description>
<pubDate>2014/4/23 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Xiao-Yu Zhang,Xiao-Fan Guo,Shao-Dan Zhang,Jing-Na He,Cao-Yu Sun,Yin Zou,Han-Si Bi and Yang Qu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Xiao-Yu Zhang,Xiao-Fan Guo,Shao-Dan Zhang,Jing-Na He,Cao-Yu Sun,Yin Zou,Han-Si Bi and Yang Qu</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140230]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Measuring quality of life in oculoplastic patients]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140125]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To investigate if there is any published evidence of impaired quality of life in conditions which are corrected by oculoplastic surgery and whether there is proven benefit in the quality of life such procedures. <b>METHODS:</b> We searched a number of databases to determine the level of evidence available for common conditions amenable to oculoplastic surgery. Search terms concentrated on quality of life measures rather than anatomical correction of deformities.<b>RESULTS:</b> The level of evidence available for different conditions was very variable. Certain conditions had extensive research documenting reduction in quality of life, with some evidence for improvement after surgery. Some other common conditions had little or no evidence supporting of reduction in quality of life to support the need for surgery.<b>CONCLUSION:</b>The evidence is sparse for quality of life improvement after some of our most commonly performed procedures. Many of these procedures are now being identified by primary care trusts (PCTs) as of “low clinical value”, and are no longer being routinely commissioned in certain parts of the UK. There is a need to address this lack of evidence to determine whether oculoplastic surgery should continue to be commissioned by PCTs.]]></description>
<pubDate>2014/2/20 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Edward Ridyard and Clare Inkster]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Edward Ridyard and Clare Inkster</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20140125]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of intravitreal bevacizumab with intravitreal triamcinolone acetonide for treatment of cystoid macular edema secondary to retinal vein occlusion: a Meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150629]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To compare the effects of intravitreal injection of bevacizumab (IVB) with intravitreal triamcinolone acetonide (IVTA) on the treatment of cystoid macular edema (CME) secondary to retinal vein occlusion (RVO).
METHODS: A literature search was conducted using PubMed, the Cochrane Central Register of Controlled Trials, Web of Science and the Chinese Biomedical Database. The comparison was divided into two groups, group 1 conducted comparison in branch RVO (BRVO) or central RVO (CRVO), group 2 conducted comparison in ischemic-RVO or nonischemic-RVO. Pooled mean differences (MDs) for changes in visual acuity (VA), central macular thickness (CMT) and intraocular pressure (IOP) were calculated in groups at 4, 12 and 24wk after treatment respectively.
RESULTS: Eight studies comparing the efficacy of IVB with IVTA were included in the Meta-analysis. In group 1, in BRVO, significant difference was shown on the comparison of CMT at 24wk (MD, -45.66; 95% CI, -76.03 to -15.28; P=0.003), IVB was effective on BRVO for at least 24wk; no significant differences were found in the comparison of VA at each time points (P>0.05 respectively). In CRVO, no significant differences were found in the comparison of VA or CMT between IVB and IVTA at each time points (P>0.05, respectively). In group 2, in ischemic-RVO, significant differences were shown in the comparison of VA (MD, -0.28; 95% CI, -0.42 to -0.14; P<0.0001) and CMT (MD, -86.50; 95% CI, -151.18 to -22.43; P=0.008) at 24wk; In nonischemic-RVO, no significant differences were demonstrated in the comparison of VA or CMT between IVB and IVTA at each time points (P>0.05, respectively). The occurrence of high IOP was much lower in IVB group.
CONCLUSION: This Meta-analysis suggested that IVB was effective in decreasing CMT in BRVO for at least 24wk, IVB is more effective on improving VA and reducing CMT in ischemic-RVO. IVB is more promising on RVO than IVTA.]]></description>
<pubDate>2015/11/12 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Yan Sun and Yi Qu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yan Sun and Yi Qu</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150629]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy:a systematic review and Meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150536]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To compare the efficacy of intravitreal ranibizumab (IVR) alone or in combination with photodynamic therapy (PDT) <i>vs</i> PDT in patients with symptomatic polypoidal choroidal vasculopathy (PCV).<b>METHODS:</b> A systematic search of a wide range of databases (including PubMed, EMBASE, Cochrane Library and Web of Science) was searched to identify relevant studies. Both randomized controlled trials (RCTs) and non-RCT studies were included. Methodological quality of included literatures was evaluated according to the Newcastle-Ottawa Scale. RevMan 5.2.7 software was used to do the Meta-analysis.<b>RESULTS:</b> Three RCTs and 6 retrospective studies were included. The results showed that PDT monotherapy had a significantly higher proportion in patients who achieved complete regression of polyps than IVR monotherapy at months 3, 6, and 12 (All <i>P</i>≤0.01), respectively. However, IVR had a tendency to be more effective in improving vision on the basis of RCTs. The proportion of patients who gained complete regression of polyps revealed that there was no significant difference between the combination treatment and PDT monotherapy. The mean change of best-corrected visual acuity (BCVA) from baseline showed that the combination treatment had significant superiority in improving vision <i>vs</i> PDT monotherapy at months 3, 6 and 24 (All <i>P</i>&lt;0.05), respectively. In the mean time, this comparison result was also significant at month 12 (<i>P</i>&lt;0.01) after removal of a heterogeneous study.<b>CONCLUSION:</b> IVR has non-inferiority compare with PDT either in stabilizing or in improving vision, although it can hardly promote the regression of polyps. The combination treatment of PDT and IVR can exert a synergistic effect on regressing polyps and on maintaining or improving visual acuity. Thus, it can be the first-line therapy for PCV.]]></description>
<pubDate>2015/10/9 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Kai Tang,Jun-Kang Si,Da-Dong Guo,Yan Cui,Yu-Xiang Du,Xue-Mei Pan and Hong-Sheng Bi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Kai Tang,Jun-Kang Si,Da-Dong Guo,Yan Cui,Yu-Xiang Du,Xue-Mei Pan and Hong-Sheng Bi</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150536]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Bare sclera resection followed by mitomycin C and/or autograft limbus conjunctiva in the surgery for pterygium:a Meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150537]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b>Toevaluate the recurrence andcomplicationsafter bare sclera resection (BSR) combined with mitomycin C (MMC) treatment and/or autograft limbus conjunctiva (ALC) in the surgery for pterygium.<b>METHODS:</b>Meta-analysis was used to evaluate the differences in patient outcomes between BSR of pterygium with or without MMC and/or ALC. All included studies were randomized trials of patients with pterygium who received BSR followed by MMC and/or ALC in the surgery. The recurrence of pterygium and other complications resulting from different treatments were extracted for analysis.<b>RESULTS</b>:Thirteen studies met the inclusion criteria. The recurrence of pterygium with intraoperative (IO) MMC was higher than that with ALC (OR=2.38，95% confidence interval 1.45-3.91, <i>I</i><sup>2</sup>=29%). Postoperative MMC resulted in an incidence of recurrence similar to that of ALC (OR=0.66, 95% confidence interval 0.30-1.42, <i>I</i><sup>2</sup>=0%), and IO MMC treatment in combination with ALC produced similar patient outcomes to ALC alone (OR=0.41, 95% confidence interval 0.16-1.01, <i>I</i><sup>2</sup>=16%). Other complications such as punctate epitheliopathy, scleral thinning and ischemia, irritation and persistent epithelium defect, were more common in patients in the MMC group as compared to those treated with ALC.<b>CONCLUSION:</b>The recurrence of pterygium with BSR followed by ALC is lower than that of BSR followed by MMC, and the incidence of other complications is lower. While ALC is a more effective strategy for treating pterygium, the quality of the ALC transplant should be considered when the patient has a history of glaucoma.]]></description>
<pubDate>2015/10/9 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Tan Long and Zhi Li]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Tan Long and Zhi Li</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150537]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Natamycin in the treatment of fungal keratitis:a systematic review and Meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150329]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To review published clinical studies examining the effect of natamycin in the treatment of fungal keratitis.<b>METHODS:</b>We selected the publications in CENTRAL, MEDLINE, EMBASE, CNKI, and CBM. This study systematically reviewed published randomized controlled trials (RCTs) that compared natamycin to other antifungal agents, and conducted feasible Meta-analysis of efficacy results using Revman 5.2 software.<b>RESULTS:</b> We included seven trials which were mainly carried out in developing countries of Asia, with five trials conducted in India, one each in China and Bangladesh. A total of 804 participants were randomized to following comparisons:2% econazole versus 5% natamycin showed little difference in the effects of treatment of fungal keratitis [RR=0.99, 95% confidence interval (CI), 0.8 to 1.21]; chlorhexidine gluconate versus 5% natamycin indicated that the results on healing of the ulcer at 21d was less conclusive (RR=0.77, 95% CI, 0.55 to 1.08; <i>I</i><sup>2</sup>=0%); 1% voriconazole versus 5% natamycin suggested that natamycin treatment appeared to be significantly better outcomes than voriconazole (regression coefficient =-0.18 logMAR; 95% CI, -0.30 to -0.05; <i>P</i>=0.006), especially in <i>Fusarium</i> cases (regression coefficient=-0.41 logMAR; 95% CI, -0.61 to -0.20; <i>P</i>&lt;0.001); natamycin versus fluconazole showed a significant difference in cure rate (χ<sup>2</sup> =5.048, <i>P</i>&lt;0.05) and natamycin group was more effective than fluconazole in average period of therapy (<i>t</i>=7.94, <i>P</i>&lt;0.01).<b>CONCLUSION:</b> Natamycin was a preferable choice in the treatment of fungal keratitis, especially in the early period of<i> Fusarium</i> cases.]]></description>
<pubDate>2015/6/9 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Sheng Qiu,Gui-Qiu Zhao,Jing Lin,Xue Wang,Li-Ting Hu,Zhao-Dong Du,Qian Wang and Cheng-Cheng Zhu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Sheng Qiu,Gui-Qiu Zhao,Jing Lin,Xue Wang,Li-Ting Hu,Zhao-Dong Du,Qian Wang and Cheng-Cheng Zhu</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150329]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Meta-analysis of association between K469E polymorphism of the ICAM-1 gene and retinopathy in type 2 diabetes]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150330]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b>To collectively evaluate the association of intercellular adhesion molecule-1 (ICAM-1) gene K469E polymorphism (rs5498) with diabetic retinopathy (DR) in patients with type 2 diabetic mellitus (T2DM).<b>METHODS:</b>Overall review of available literatures relating K469E polymorphism to the risk of DR was conducted on 4 electronic databases. Meta-analysis was performed by Stata 12.0 to calculate pooled odds ratios (ORs). Potential sources of heterogeneity and bias were explored.<b>RESULTS:</b>Seven studies with genotype frequency data including 1120 cases with DR and 956 diabetic controls free of DR were included. Meta-analysis did not show significant association of K469E polymorphism with DR (<i>P</i>&gt;0.05). A statistically significant association was detected between the K469E polymorphism and proliferative diabetic retinopathy (PDR) in Asians only in dominant model (GG+AG <i>vs </i>AA) with pooled OR of 0.729 (95%CI:0.564-0.942, <i>P</i>=0.016, <i>P</i>heterogeneity=0.143), however, this association was not detected in recessive model (GA+AA <i>vs </i>GG; OR=1.178, 95%CI:0.898-1.545, <i>P</i>=0.236, <i>P</i>heterogeneity=0.248) or allelic model (G <i>vs</i> A; OR=0.769, 95% CI:0.576-1.026, <i>P</i>=0.074, <i>P</i>heterogeneity=0.094). No publication bias was found by Funnel plot, Begg''s and Egger''s test.<b>CONCLUSION:</b>This research found no statistically significant association between ICAM-1 gene K469E polymorphism and DR in patients with T2DM, but showed significant association of the K469E polymorphism with PDR in Asian diabetic patients only in dominant model. Further investigation would be required to consolidate the conclusion.]]></description>
<pubDate>2015/6/9 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Wen-Ying Fan and Ning-Pu Liu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Wen-Ying Fan and Ning-Pu Liu</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150330]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Association between SERPING1 rs2511989 polymorphism and age-related macular degeneration: Meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150231]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To investigate the association between SERPING1 rs2511989 (G>A) polymorphism and age-related macular degeneration (AMD).
METHODS: A number of electronic databases (up to July 15, 2014) were searched independently by two investigators. A Meta-analysis was performed on the association between SERPING1 rs2511989 polymorphism and AMD. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were estimated.
RESULTS: Eight studies with 16 cohorts consisting of 9163 cases and 6813 controls were included in this Meta-analysis. There was no significant association between rs2511989 polymorphism and AMD under all genetic models in overall estimates (A vs G: OR= 0.938, 95%CI =0.858-1.025; AA vs GG:OR =0.871, 95%CI =0.719-1.056; AG vs GG: OR =0.944, 95%CI =0.845-1.054; AA+AG vs GG: OR =0.927, 95% CI =0.823-1.044; AA vs AG+GG: OR =0.890, 95%CI =0.780-1.034). Cumulative Meta-analyses also showed a trend of no association between rs2511989 polymorphism and AMD as information accumulated by year. Subgroup analysis and Meta-regression analysis indicated that age-matching status was the main source of heterogeneity. Sensitivity analysis found the results in overall comparisons and subgroup comparisons of white subjects under the allele model were found to have significantly statistical differences after studies deviating from Hardy-Weinberg equilibrium (HWE) were excluded (overall: OR=0.918, 95%CI = 0.844-0.999, P =0.049; whites: OR =0.901, 95%CI = 0.817-0.994, P =0.038). However, the results were not sufficiently robust for further sensitivity analysis and statistical differences disappeared on applying Bonferroni correction (with a significance level set at 0.05/25).
CONCLUSION: This Meta-analysis indicates that SERPING1 rs2511989 polymorphism and AMD tend to have no association with each other. Age matching status is a big confounding factor, and more studies with subtle designs are warranted in future.]]></description>
<pubDate>2015/4/16 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Yi Dong,Ze-Dong Li,Xin-Yu Fang,Xue-Feng Shi,Song Chen and Xin Tang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yi Dong,Ze-Dong Li,Xin-Yu Fang,Xue-Feng Shi,Song Chen and Xin Tang</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150231]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Bioinformatics analysis of potential essential genes that response to the high intraocular pressure on astrocyte due to glaucoma]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150232]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AIM: To study the gene expression response and predict the network in cell due to pressure effects on optic nerve injury of glaucoma.
METHODS: We used glaucoma related microarray data in public database [Gene Expression Omnibus (GEO)] to explore the potential gene expression changes as well as correspondent biological process alterations due to increased pressure in astrocytes during glaucoma development. 
RESULTS: A total of six genes were identified to be related with pressure increasing. Through the annotation and network analysis, we found these genes might be involved in cell morphological remodeling, angiogenesis, mismatch repair. 
CONCLUSION: Increasing pressure in glaucoma on astrocytes might cause gene expression alterations, which might induce some cellular responses changes.]]></description>
<pubDate>2015/4/16 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Yang Yang,Jing-Zhu Duan,Yu Di,Dong-Mei Gui and Dian-Wen Gao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yang Yang,Jing-Zhu Duan,Yu Di,Dong-Mei Gui and Dian-Wen Gao</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150232]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150126]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To systematically compare the efficacy and safety of off-label bevacizumab versus licensed ranibizumab intravitreal injections as well as monthly regimen versus pro re nata [PRN (as needed)] regimen in the treatment of neovascular age-related macular degeneration (nAMD).
<b>METHODS:</b> Relevant publications were identified through automatically retrieve of database and manually retrieving. The methodological quality of studies included was assessed using the Jadad score and the risk-of-bias assessment. The efficacy estimates were measured by the weight mean difference (WMD) for the improvement of best-corrected visual acuity (BCVA) and central retinal thickness (CRT) reduction. The safety estimates were measured by odds ratios (OR) for adverse events rates. Statistical analysis was conducted by Revman 5.2.7. 
<b>RESULTS:</b> Seven studies were included in the Meta-analysis. There were no statistically significant differences between bevacizumab and ranibizumab in BCVA at 1 and 2y (P=0.37, P=0.18, respectively), However, both drugs has better BCVA given monthly than given as needed at 1 and 2y (P<0.05). The results demonstrated the mean decrease in CRT was less in bevacizumab group than ranibizumab group at 1y (P<0.05), while the difference was not significant at 2y (P=0.24). Treatment monthly gained much more decrease in CRT at 1 and 2y (P<0.005). There were no differences between drugs in the rates of death, arterial thrombotic events and venous thrombotic events (P=0.41, P=0.55, P=0.10, respectively), while the rates of medical dictionary for regulatory activities (MedDAR) system organ class events and ≥1 systemic serious adverse events were higher in bevacizumab group than ranibizumab group (P<0.05). But the incidences of death, arterial thrombotic events, venous thrombotic events, MedDAR system organ class events as well as ≥1 systemic serious adverse events were not statistically different between both treatment regimens of monthly and as needed (P=0.14, P=0.76, P=0.73, P=0.12, P=0.11, respectively).
<b>CONCLUSION:</b> Bevacizumab was equivalent to ranibizumab for BCVA, however bevacizumab tended to gain less decrease in CRT and had higher rates of serious adverse events. Compared with treatment as needed, treatment monthly showed superior efficacy in BCVA improvement and CRT reduction, while the rates of adverse events were similar in the two dosing regimens.]]></description>
<pubDate>2015/2/13 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Wen-Jie Wang,Jian Chen,Xiao-Ling Zhang,Min Yao,Xiao-Yong Liu,Qing Zhou and Yi-Xin Qu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Wen-Jie Wang,Jian Chen,Xiao-Ling Zhang,Min Yao,Xiao-Yong Liu,Qing Zhou and Yi-Xin Qu</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150126]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Treatment of hydrofluoric acid exposure to the eye]]></title>
<link><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150128]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>AIM:</b> To review the current evidence of the treatment of hydrofluoric acid (HF) exposure to the human cornea.
<b>METHODS:</b> A comprehensive manual search of the literature was conducted through the Ovid interface to assess the mechanism and efficacy of each irrigator through a variety of clinical cases and experimental studies.
<b>RESULTS:</b> Ocular exposure to HF is extremely damaging to the eye and swift recognition and decontamination with an appropriate agent forms the basis of treatment. Although there are various decontamination solutions that have efficacy against the corrosive action of HF, irrigation with Hexafluorine proved to be the most safe and effective treatment for the eye.
<b>CONCLUSION:</b> In conclusion emergency departments could benefit from the availability of Hexafluorine for the treatment of HF ocular burns in patients.]]></description>
<pubDate>2015/2/13 0:00:00</pubDate>
<category><![CDATA[Informatics Research]]></category>
<author><![CDATA[Katherine Atley and Edward Ridyard]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Katherine Atley and Edward Ridyard</atom:name>
</atom:author>
<guid><![CDATA[http://www.ijo.cn/gjyken/article/abstract/20150128]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>